COVID-19 vaccine safety and side effects in children aged 5-11 years : a cross-sectional study
INTRODUCTION: The COVID-19 pandemic has prompted a global drive for vaccination, including children. Despite the urgency, understanding the safety and side effects remains crucial. Our study aimed to evaluate the safety of the Pfizer- BioNTech (BNT162b2) vaccine in children by determining the proportion of vaccinated children who experienced side effects and identifying factors associated with postvaccination side effects.
MATERIALS AND METHODS: A cross-sectional study was conducted among children who received the COVID-19 vaccine between 3 February and 8 May 2022. Data were collected using a self-administered questionnaire filled out by the parent or legal guardian.
RESULTS: The mean age of the study participants was 9 years old and 43.1% were males. Out of the 195 participants in the study, 62 (31.8%) reported side effects after vaccination. The most frequently reported side effects were pain at the injection site (29.7%, n=58), fever (15.9%, n=31), localised inflammation (10.8%, n=21) and arthralgia/myalgia (9.2%, n=18). There were no reported severe adverse events such as anaphylaxis or myocarditis. Most side effects occurred within the first two days post-vaccination. There was a higher proportion of side effects among children with underlying co-morbidities. No significant differences were observed based on age, weight, ethnicity and the presence of allergies, or the use of premedication.
CONCLUSION: The BNT162b2 vaccine was generally welltolerated in children, with most side effects being mild and self-limiting. These findings support the safety of the COVID-19 vaccine and would guide healthcare professionals, parents and policy-makers in making informed decisions about COVID-19 vaccination, especially among high-risk groups.
| Medienart: |
Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:78 |
|---|---|
| Enthalten in: |
The Medical journal of Malaysia - 78(2023), 6 vom: 29. Nov., Seite 803-807 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Nurhani, M A [VerfasserIn] |
|---|
| Themen: |
|---|
| Anmerkungen: |
Date Completed 01.12.2023 Date Revised 01.12.2023 published: Print Citation Status MEDLINE |
|---|
| Förderinstitution / Projekttitel: |
|
|---|
| PPN (Katalog-ID): |
NLM365223646 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM365223646 | ||
| 003 | DE-627 | ||
| 005 | 20231226101219.0 | ||
| 007 | tu | ||
| 008 | 231226s2023 xx ||||| 00| ||eng c | ||
| 028 | 5 | 2 | |a pubmed24n1217.xml |
| 035 | |a (DE-627)NLM365223646 | ||
| 035 | |a (NLM)38031224 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Nurhani, M A |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a COVID-19 vaccine safety and side effects in children aged 5-11 years |b a cross-sectional study |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ohne Hilfsmittel zu benutzen |b n |2 rdamedia | ||
| 338 | |a Band |b nc |2 rdacarrier | ||
| 500 | |a Date Completed 01.12.2023 | ||
| 500 | |a Date Revised 01.12.2023 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a INTRODUCTION: The COVID-19 pandemic has prompted a global drive for vaccination, including children. Despite the urgency, understanding the safety and side effects remains crucial. Our study aimed to evaluate the safety of the Pfizer- BioNTech (BNT162b2) vaccine in children by determining the proportion of vaccinated children who experienced side effects and identifying factors associated with postvaccination side effects | ||
| 520 | |a MATERIALS AND METHODS: A cross-sectional study was conducted among children who received the COVID-19 vaccine between 3 February and 8 May 2022. Data were collected using a self-administered questionnaire filled out by the parent or legal guardian | ||
| 520 | |a RESULTS: The mean age of the study participants was 9 years old and 43.1% were males. Out of the 195 participants in the study, 62 (31.8%) reported side effects after vaccination. The most frequently reported side effects were pain at the injection site (29.7%, n=58), fever (15.9%, n=31), localised inflammation (10.8%, n=21) and arthralgia/myalgia (9.2%, n=18). There were no reported severe adverse events such as anaphylaxis or myocarditis. Most side effects occurred within the first two days post-vaccination. There was a higher proportion of side effects among children with underlying co-morbidities. No significant differences were observed based on age, weight, ethnicity and the presence of allergies, or the use of premedication | ||
| 520 | |a CONCLUSION: The BNT162b2 vaccine was generally welltolerated in children, with most side effects being mild and self-limiting. These findings support the safety of the COVID-19 vaccine and would guide healthcare professionals, parents and policy-makers in making informed decisions about COVID-19 vaccination, especially among high-risk groups | ||
| 650 | 4 | |a Journal Article | |
| 650 | 7 | |a BNT162 Vaccine |2 NLM | |
| 650 | 7 | |a COVID-19 Vaccines |2 NLM | |
| 700 | 1 | |a Farah, H M S |e verfasserin |4 aut | |
| 700 | 1 | |a Ili, N M A |e verfasserin |4 aut | |
| 700 | 1 | |a Zahidah, A R |e verfasserin |4 aut | |
| 700 | 1 | |a Rahimah, B |e verfasserin |4 aut | |
| 700 | 1 | |a Nabilah, H K |e verfasserin |4 aut | |
| 700 | 1 | |a Gan, L L |e verfasserin |4 aut | |
| 700 | 1 | |a David, N C E |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t The Medical journal of Malaysia |d 1972 |g 78(2023), 6 vom: 29. Nov., Seite 803-807 |w (DE-627)NLM000278386 |x 0300-5283 |7 nnns |
| 773 | 1 | 8 | |g volume:78 |g year:2023 |g number:6 |g day:29 |g month:11 |g pages:803-807 |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 78 |j 2023 |e 6 |b 29 |c 11 |h 803-807 | ||